Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene

[1]  Kishore Shetty,et al.  Hormone replacement therapy , 2002, BMJ : British Medical Journal.

[2]  M. Borovský.  [Hormone replacement therapy and osteoporosis]. , 2000, Bratislavske lekarske listy.

[3]  G. Figtree,et al.  Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. , 1999, Circulation.

[4]  B. Mitlak,et al.  Selective estrogen receptor modulators: a look ahead. , 1999, Drugs.

[5]  S. Hoffman,et al.  Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. , 1998, Endocrinology.

[6]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[7]  S. Rosenkranz,et al.  Estrogen modulates AT1 receptor gene expression in vitro and in vivo. , 1998, Circulation.

[8]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[9]  R. Dietz,et al.  Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. , 1997, Circulation.

[10]  D. Harrison.  Endothelial Function and Oxidant Stress , 1997, Clinical cardiology.

[11]  B. Psaty,et al.  Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. , 1997, Archives of internal medicine.

[12]  R. Vogel.  Coronary risk factors, endothelial function, and atherosclerosis: A review , 1997, Clinical cardiology.

[13]  S. Rajagopalan,et al.  Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. , 1997, Circulation.

[14]  U. Ikeda,et al.  Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy , 1997, Clinical cardiology.

[15]  H. Jo,et al.  Nitric oxide, free radicals and cell signalling in cardiovascular disease. , 1997, Biochemical Society transactions.

[16]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[17]  J. Liao,et al.  Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.

[18]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[19]  R. Alexander,et al.  Angiotensin II receptor pharmacology. , 1994, Advances in pharmacology.

[20]  A. Folsom,et al.  Association of Hormone-Replacement Therapy With Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[21]  N. Wenger,et al.  Cardiovascular health and disease in women. , 1993, The New England journal of medicine.

[22]  A. Folsom,et al.  Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[23]  S. Harlap.  The benefits and risks of hormone replacement therapy: an epidemiologic overview. , 1992 .

[24]  M. Hong,et al.  Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. , 1992, The American journal of cardiology.

[25]  A. Whittemore,et al.  Menopause and the risk of coronary heart disease in women. , 1987, The New England journal of medicine.